Immunopathogenesis of HIV-related heart muscle disease: current perspectives.
As more effective antiretroviral therapies improve survival times, growing numbers of HIV-positive patients are at risk of developing end-organ damage or neoplasia. Heart muscle disease is the most important cardiovascular manifestation of HIV infection and seems set to become increasingly prevalent. This may take the form of either a dilated cardiomyopathy or isolated left or right ventricular dysfunction, is associated with a poor prognosis, and results in symptomatic heart failure in up to 5% of HIV patients. The precise cause of HIV-associated cardiomyopathy remains unclear but is undoubtedly complex, and most probably multifactorial. This report examines our current understanding of the immunopathogenesis of HIV-associated cardiomyopathy.
Currie
Peter F
PF
Perth Royal Infirmary, Perth, UK.
Boon
Nicholas A
NA
D017088:AIDS-Related Opportunistic Infections; D019380:Anti-HIV Agents / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000821:virology; D015658:HIV Infections; D006801:Humans; D009205:Myocarditis / Q000821:virology*; D009748:Nutrition Disorders / Q000821:virology; D018754:Ventricular Dysfunction / Q000821:virology; D015215:Zidovudine / Q000009:adverse effects
D019380:Anti-HIV Agents; D015215:Zidovudine